Cargando…

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Górriz, Jose Luis, Nieto, Javier, Navarro-González, Juan F., Molina, Pablo, Martínez-Castelao, Alberto, Pallardó, Luis M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626660/ https://www.ncbi.nlm.nih.gov/pubmed/26512703 http://dx.doi.org/10.3390/jcm4101866

Ejemplares similares

The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years
por: Martínez-Castelao, Alberto, et al.
Publicado: (2015)

Determination of Hypoglycemic, Hypolipidemic and Nephroprotective Effects of Berberis Calliobotrys in Alloxan-Induced Diabetic Rats
por: Rasool, Shahid, et al.
Publicado: (2023)

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
por: Mosterd, Charlotte M., et al.
Publicado: (2020)

Oral hypoglycemic agents: do the ends justify the means?
por: Langer, Oded
Publicado: (2015)

Presbycusis: do we have a third ear?()
por: Reis, Luis Roque, et al.
Publicado: (2016)

New hypoglycemic agents and the kidney: what do the major trials tell us?
por: Smyth, Brendan, et al.
Publicado: (2018)

Adherence to Oral Hypoglycemic Agents in Hawaii
por: Lee, Rachel, et al.
Publicado: (2005)

Antibiotic Discovery: Where Have We Come from, Where Do We Go?
por: Ribeiro da Cunha, Bernardo, et al.
Publicado: (2019)

The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?
por: Agarwal, Rajiv, et al.
Publicado: (2011)

Do We Have the Spark?
por: Rupel, Valentina Prevolnik, et al.
Publicado: (2022)

A nephroprotective iodinated contrast agent with cardioprotective properties: A pilot study
por: Rowe, Elizabeth S., et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
por: Górriz, José Luis, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

Nephroprotective Properties of Antidiabetic Drugs
por: Gerdes, Christian, et al.
Publicado: (2023)

Hypoglycemic agents and potential anti-inflammatory activity
por: Kothari, Vishal, et al.
Publicado: (2016)

Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?
por: Ottewell, Penny, et al.
Publicado: (2019)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Optimizing the timing of nephrology referral for patients with diabetic kidney disease
por: Martínez-Castelao, Alberto, et al.
Publicado: (2020)

Why Do We Have Fingerprints?
Publicado: (2009)

Infectious diseases and cognition: do we have to worry?
por: Hernandez-Ruiz, Virgilio, et al.
Publicado: (2022)

Mechanisms of Herbal Nephroprotection in diabetes mellitus
por: Dragoș, Dorin, et al.
Publicado: (2020)

New Insights into the Nephroprotective Potential of Lercanidipine
por: Hajdys, Joanna, et al.
Publicado: (2023)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
por: España Fernandez, Sofia, et al.
Publicado: (2023)

The Management of Type 2 Diabetic Patients with Hypoglycemic Agents
por: Carnevale Schianca, G. P., et al.
Publicado: (2012)

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
por: Ge, Derek, et al.
Publicado: (2022)

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?
por: D’Marco, Luis, et al.
Publicado: (2021)

Vitamin E Is a Nephroprotectant Agent in Male but Not in Female in a Model of Cisplatin-Induced Nephrotoxicity
por: Jilanchi, Sima, et al.
Publicado: (2013)

Phytochemical evaluation of roots of Plumbago zeylanica L. and assessment of its potential as a nephroprotective agent
por: Rajakrishnan, R., et al.
Publicado: (2017)

Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?
por: Morillas, Carlos, et al.
Publicado: (2021)

Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma
por: Osca-Verdegal, Rebeca, et al.
Publicado: (2022)

Do we need contrast agents for EUS?
por: Saftoiu, Adrian, et al.
Publicado: (2020)

Antioxidant-Based Therapies in Male Infertility: Do We Have Sufficient Evidence Supporting Their Effectiveness?
por: Amorini, Angela Maria, et al.
Publicado: (2021)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
por: Kassem, Sameer A., et al.
Publicado: (2009)

Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents
por: Xu, Bilin, et al.
Publicado: (2022)

Drugs for malaria elimination: what do we have now and what do we need?
por: Shanks, Dennis
Publicado: (2014)

Nephroprotective Effect of Heparanase in Experimental Nephrotic Syndrome
por: Assady, Suheir, et al.
Publicado: (2015)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Nephroprotection by SGLT2 Inhibition: Back to the Future?
por: De Nicola, Luca, et al.
Publicado: (2020)

Nephroprotective, cytotoxic and antioxidant activities of Euphorbia paralias
por: Al-Yousef, Hanan M., et al.
Publicado: (2021)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ltk6bmk6nf59jo3jv7hcikfou5